Cancer Antigen (CA) 125
Also known as: CA-125, Second Generation Assay
Use
The Elecsys CA 125 II assay is labeled "For in vitro diagnostic use" in the manufacturer's package insert.1
Special Instructions
Values obtained with different assay methodologies should not be used interchangeably in serial testing. It is recommended to use only one assay method consistently to monitor a patient's course of therapy. This test may exhibit interference from high-dose biotin supplementation, which should be stopped at least 72 hours prior to sample collection.
Limitations
The measured CA 125 value can vary depending on the test procedure used, and values determined by different test procedures cannot be directly compared, potentially causing erroneous interpretations. Interference may occur from patients treated with monoclonal mouse antibodies or those with high titers of antibodies to streptavidin and ruthenium. The test's results should always be assessed with the patient's medical history, clinical examination, and other findings.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 10334-1
- 10334-1
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.7 mL
Container
Gel-barrier tube (preferred) or red-top tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Patient Preparation
Assay should not be performed until at least three weeks after primary chemotherapy and two months following abdominal surgery.
Storage Instructions
Room temperature
Causes for Rejection
Citrate plasma specimen; improper labeling
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |